Summary
It was shown in the present study that the selective non-competitive N-methyl-D-aspartate (NMDA) antagonist MK-801 [(+)-5-methyl-10,11-dihydroxy-5H-dibenzo(a,d)cyclohepten-5,10-imine] caused a pronounced and dose-dependent increase in locomotion in mice pretreated with a combination of reserpine and α-methyl-para-tyrosine. Haloperidol pretreatment did not antagonize the MK-801-induced stimulation of locomotion. The findings are discussed in relation to the concept of a corticostriatothalamocortical negative feedback loop serving to protect the cortex from an overload of information and hyperarousal. Such a feedback loop would encompass i.a. corticostriatal glutamatergic neurons and it would be modulated by mesencephalostriatal dopaminergic neurons.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1: 179–186
Clineschmidt BV, Martin GE, Buntin PR (1982a) Anticonvulsant activity of (+)-5-methyl-10,1 1-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2: 123–134
Clineschmidt BV, Martin GE, Bunting PR, Papp NL (1982b) Central sympathomimetic activity of (+)-5-methyl-10-11-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2: 135–145
Clineschmidt BV, Williams M, Witoslawski JJ, Bunting PR, Risley EA, Totaro JA (1982c) Restoration of shock-suppressed behavior by treatment with (+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2: 147–163
Gill R, Foster AC, Woodruff GN (1987) Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil. J Neurosci 7: 3343–3349
Kim JS, Kornhuber HH, Kornhuber J, Kornhuber ME (1985) Glutamic acid and the dopamine hypothesis of schizophrenia. In: Shagass C et al (eds) Biological psychiatry. Elsevier, Amsterdam New York, pp 1109–1111
Koek W, Woods JH, Winger GD (1988) MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys. J Pharmacol Exp Ther 245: 969–974
Kornhuber HH, Kornhuber J, Kim JS, Kornhuber ME (1984) Zur biochemischen Theorie der Schizophrenie. Nervenarzt 55: 602–606
McNamara JO, Russell RD, Rigsbee L, Bonhaus DW (1988) Anticonvulsant and anti-epileptogenic actions of MK-801 in the kindling and electroshock models. Neuropharmacology 27: 563–568
Schmidt WJ, Bubser M (1989) Anti-cataleptic effects of the N-methyl-aspartate antagonist MK-801. Pharmacol Biochem Behav (in press)
Schmidt WJ, Bury D (1988) Behavioural effects of N-methyl-D-aspartate in the anterodorsal striatum of the rat. Life Sci 43: 545–549
Sonsalla PK, Nicklas WJ, Heikkila E (1988) A role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science (in press)
Wong EHF, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL (1986) The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA 83: 7104–7108
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carlsson, M., Carlsson, A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transmission 75, 221–226 (1989). https://doi.org/10.1007/BF01258633
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01258633